Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Rendeiro AF, Vorkas CK, Krumsiek J, Singh HK, Kapadia SN, Cappelli LV, et al. Metabolic and Immune Markers for Precise Monitoring of COVID-19 Severity and Treatment. Front Immunol. 2021;12:809937.

Cacciatore S, Wium M, Licari C, Ajayi-Smith A, Masieri L, Anderson C, et al. Inflammatory metabolic profile of South African patients with prostate cancer. Cancer Metab. 2021;9(1):29.

Yang HS, Hou Y, Zhang H, Chadburn A, Westblade LF, Fedeli R, et al. Machine Learning Highlights Downtrending of COVID-19 Patients with a Distinct Laboratory Profile. Health Data Sci. 2021;2021:7574903.

Weiner AB, Vidotto T, Liu Y, Mendes AA, Salles DC, Faisal FA, et al. Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nat Commun. 2021;12(1):935.

Romero-Velez G, Pereira X, Yang J, Panarelli NC, McAuliffe JC. Neuroendocrine Tumor of the Common Bile Duct Associated With von Hippel-Lindau Disease. ACG Case Rep J. 2021;8(2):e00512.

Kubiak J, Davidson E, Soave R, Kodiyanplakkal RP, Robertson A, van Besien K, et al. Colonization with Gastrointestinal Pathogens Prior to Hematopoietic Cell Transplantation and Associated Clinical Implications. Transplant Cell Ther. 2021;27(6):499.e1-499.e6.

Magro C, Nuovo G, J Mulvey J, Laurence J, Harp J, A Crowson N. The skin as a critical window in unveiling the pathophysiologic principles of COVID-19. Clin Dermatol. 2021;39(6):934-965.

Tang X-, Melis M, Lu C, Rappa A, Zhang T, Jessurun J, et al. A retinoic acid receptor β2 agonist attenuates transcriptome and metabolome changes underlying nonalcohol-associated fatty liver disease. J Biol Chem. 2021;297(6):101331.

Centenera MM, Scott JS, Machiels J, Nassar ZD, Miller DC, Zinonos I, et al. ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer. Cancer Res. 2021;81(7):1704-1718.

Bastos DC, Ribeiro CF, Ahearn T, Nascimento J, Pakula H, Clohessy J, et al. Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss. J Pathol. 2021;253(3):292-303.